Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report

The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Liang-Wei, Chang, John Wen-Cheng, Wu, Chiao-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570266/
https://www.ncbi.nlm.nih.gov/pubmed/36233109
http://dx.doi.org/10.3390/ijms231911809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570266/
https://www.ncbi.nlm.nih.gov/pubmed/36233109
http://dx.doi.org/10.3390/ijms231911809

Ejemplares similares